CIMC Enric (3899) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
3 Dec, 2025Executive summary
Revenue increased 6.7% year-over-year to RMB11.48 billion, driven by a 25.1% surge in clean energy and 14.7% growth in liquid food, while chemical and environmental segment revenue declined 47.1%.
Net profit attributable to shareholders decreased by 14.5% year-over-year to RMB486.1 million, with basic EPS down 14.8% to RMB0.241.
Gross profit margin declined to 14.3% from 16.5% in the prior year, mainly due to margin compression in chemical and environmental and liquid food segments.
Newly signed orders reached RMB16.4 billion, up 29.5% year-over-year, and backlog orders hit a record RMB29.4 billion, up 42.5%.
Clean energy and hydrogen businesses led growth, with hydrogen revenue up 65.2% to RMB450 million.
Financial highlights
Clean energy revenue accounted for 68.6% of total revenue, up from 58.5% in 1H2023; hydrogen business revenue up 65.2%.
Liquid food segment revenue increased 14.7% year-over-year to RMB2.31 billion, accounting for 20.1% of total revenue.
Chemical & environmental segment revenue declined 47.1% to RMB1.30 billion, now 11.3% of total revenue.
Overseas revenue made up 45.8% of total, with China at 54.2%.
Cash and cash equivalents rose to RMB7.25 billion as of June 30, 2024.
Outlook and guidance
Strategy focuses on expanding from equipment and engineering to comprehensive service provision, leveraging digitalization and smart technologies.
Plans to rapidly replicate the COG to hydrogen and LNG co-production model, targeting hydrogen production capacity of 200,000 tons and LNG of 1 million tons by 2027.
Anticipates continued strong demand for LNG-powered vessels and green methanol solutions, supported by policy incentives and global decarbonization trends.
Hydrogen energy business positioned for growth as national policies support industry expansion and infrastructure build-out.
Liquid food segment to focus on carbon-neutral transformation and expansion in pharmaceutical and high-growth regions.